LONDON, Jan. 30, 2017 /PRNewswire/ --
The Oncolytic Virus Landscape 2017: an analysis of pipeline,stakeholders, deals, industry trends & opportunities
The field of oncolytic viruses wasquite dormant in the first decade of the 2000s, characterized by slow clinicalprogress due to hypercautiousness and low, albeit steady, investments. Thetakeover of BioVex by Amgen in late 2011, worth
However, the efficacy ofoncolytic viruses still was modest, but can be improved when combined withimmune checkpoint inhibitors. This lead to an increased partnering interest ofthe major immuno-oncology (I-O) players, but also of investors who view oncolyticviruses as a must be for I-O combination regimens. As a consequence, total ventureequity and private investments into oncolytic virus companies in 2016 wasnearly 17-fold higher than in the year 2010.
Optimization of oncolytic virusesis ongoing and new constructs intend to solve some of the open problemsregarding the way of administration (intratumoral vs systemic), higher cancercell specific replication capacity, and longer persistence in vivo. Based onexperience with several virus families over the last decades, a few virus familiescristallized as well suitable backbones to carry more and more transgenes toexpress proteins or even single chain antibodies. This would position oncolyticviruses as independent therapeutics and could compete with immuno-oncologycompounds and cancer vaccines.
This report The Oncolytic Virus Landscape 2017: an analysis of pipeline,stakeholders, deals, industry trends & opportunities" as of January2017 brings you up-to-date regarding key players, key technologies, OncolyticVirus projects, business deals and private and public financing rounds. Thereport analyzes the Oncolytic Virus pipeline and stakeholders in the field,especially among Big Pharma/Biotech and technology companies. The reporthighlights the value of oncolytic viruses in terms of partnering terms andconditions, venture and private financing and (initial) public offerings.
This report has been built in abottom-up way by desktop search to identify and describe company, product,technology and business/financing profiles which then were evaluated andanalyzed with a final outlook describing perspectives with challenges andopportunities.
What will you find in thereport?
Who will benefit from the report?
Download the full report: https://www.reportbuyer.com/product/4659053/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith Research Advisor at Reportbuyer.com Email: email@example.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-oncolytic-virus-landscape-2017-an-analysis-of-pipeline-stakeholders-deals-industry-trends--opportunities-300399169.html
Subscribe to our Free Newsletters!